ANCA-Associated Vasculitis Clinical Presentation and Clinical Predictors of Relapse in Saudi Arabia

References

• Chen Z, Lin L, Yang W, Chen N, Lin Y. Clinical characteristics and prognostic risk factors of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV). Int Immunopharmacol. 2020;87:106819. doi:10.1016/j.intimp.2020.106819
   PubMed Web of Science ®Google Scholar
• Yates M, Watts R. ANCA-associated vasculitis. Clin Med (Northfield Il). 2017;17(1):60–64. doi:10.7861/clinmedicine.17-1-60
   PubMed Web of Science ®Google Scholar
• Guidelines-for-the-Management-of-ANCA-Associated-Vasculitis-v1.1[20754].pdf.
   Google Scholar
• Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003;349(1):36–44. doi:10.1056/NEJMoa020286
   PubMed Web of Science ®Google Scholar
• De Groot K, Rasmussen N, Bacon PA, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody–associated vasculitis. Arthritis Rheumatism. 2005;52(8):2461–2469. doi:10.1002/art.21142
   PubMed Web of Science ®Google Scholar
• de Groot K, Harper L, Jayne DR, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody—associated vasculitis: a randomized trial. Ann Intern Med. 2009;150(10):670–680. doi:10.7326/0003-4819-150-10-200905190-00004
   PubMed Web of Science ®Google Scholar
• Pagnoux C, Mahr A, Hamidou MA, et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med. 2008;359(26):2790–2803. doi:10.1056/NEJMoa0802311
   PubMed Web of Science ®Google Scholar
• Hiemstra TF, Walsh M, Mahr A, et al. Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody–associated vasculitis: a randomized controlled trial. JAMA. 2010;304(21):2381–2388. doi:10.1001/jama.2010.1658
   PubMed Web of Science ®Google Scholar
• Guillevin L, Pagnoux C, Karras A, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med. 2014;371(19):1771–1780.
   PubMed Web of Science ®Google Scholar
• Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363(3):221–232. doi:10.1056/NEJMoa0909905
   PubMed Web of Science ®Google Scholar
• Jones RB, Cohen Tervaert JW, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010;363(3):211–220. doi:10.1056/NEJMoa0909169
   PubMed Web of Science ®Google Scholar
• Pu L, Li GS, Zou YR, Zhang P, Wang L. Clinical predictors of outcome in patients with anti-neutrophil cytoplasmic autoantibody-related renal vasculitis: experiences from a single-center. Chin Med J. 2017;130(8):899–905. doi:10.4103/0366-6999.204099
   Web of Science ®Google Scholar
• Walsh M, Flossmann O, Berden A, et al. Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2012;64(2):542–548. doi:10.1002/art.33361
   PubMed Web of Science ®Google Scholar
• Oh YJ, Ahn SS, Park ES, et al. Chest and renal involvements, Birmingham vascular activity score more than 13.5 and five factor score (1996) more than 1 at diagnosis are significant predictors of relapse of microscopic polyangiitis. Clin Exp Rheumatol. 2017;35 Suppl 103(1):47–54.
   Web of Science ®Google Scholar
• Á H, Polner K, Arányi J, et al. Simple, readily available clinical indices predict early and late mortality among patients with ANCA-associated vasculitis. BMC Nephrol. 2017;18(1):76. doi:10.1186/s12882-017-0491-z
   Web of Science ®Google Scholar
• Stone JH, Hoffman GS, Merkel PA, et al. A disease-specific activity index for wegener’s granulomatosis: modification of the Birmingham vasculitis activity score. International Network for the Study of the Systemic Vasculitides (INSSYS). Arthritis Rheum. 2001;44(4):912–920. doi:10.1002/1529-0131(200104)44:4<912::AID-ANR148>3.0.CO;2-5
   PubMed Web of Science ®Google Scholar
• Mukhtyar C, Hellmich B, Jayne D, Flossmann O, Luqmani R. Remission in antineutrophil cytoplasmic antibody-associated systemic vasculitis. Clin Exp Rheumatol. 2006;24:S–93.
   Web of Science ®Google Scholar
• Wallace ZS, Miloslavsky EM. Management of ANCA associated vasculitis. BMJ. 2020;368:m421.
   Web of Science ®Google Scholar
• Murosaki T, Sato T, Akiyama Y, Nagatani K, Minota S. Difference in relapse-rate and clinical phenotype by autoantibody-subtype in Japanese patients with anti-neutrophil cytoplasmic antibody-associated vasculitis. Mod Rheumatol. 2017;27(1):95–101. doi:10.1080/14397595.2016.1192760
   PubMed Web of Science ®Google Scholar
• Al Arfaj AS, Khalil N. ANCA associated vasc ulitis in patients from Saudi Arabia. Pak J Med Sci. 2018;34(1):88. doi:10.12669/pjms.341.13881
   Web of Science ®Google Scholar
• Yoo J, Kim HJ, Jung SM, Song JJ, Park YB, Lee SW. Birmingham vasculitis activity score of more than 9.5 at diagnosis is an independent predictor of refractory disease in granulomatosis with polyangiitis. Int J Rheum Dis. 2017;20(10):1593–1605. doi:10.1111/1756-185X.13144
   Web of Science ®Google Scholar
• Solans‐Laqué R, Rodriguez‐Carballeira M, Rios‐Blanco JJ, et al. Comparison of the Birmingham vasculitis activity score and the five‐factor score to assess survival in antineutrophil cytoplasmic antibody–associated vasculitis: a study of 550 patients from Spain (REVAS Registry). Arthritis Care & ReS. 2020;72(7):1001–1010. doi:10.1002/acr.23912
   Web of Science ®Google Scholar
• Moon JS, Lee DD, Park YB, Lee SW. Rheumatoid factor false positivity in patients with ANCA-associated vasculitis not having medical conditions producing rheumatoid factor. Clin Rheumatol. 2018;37(10):2771–2779. doi:10.1007/s10067-017-3902-4
   Web of Science ®Google Scholar
• Augusto JF, Langs V, Demiselle J, et al. Low serum complement C3 levels at diagnosis of renal ANCA-associated vasculitis is associated with poor prognosis. PLoS One. 2016;11(7):e0158871. doi:10.1371/journal.pone.0158871
   PubMed Web of Science ®Google Scholar
• Choi H, Kim Y, Jung SM, Song JJ, Park YB, Lee SW. Low serum complement 3 level is associated with severe ANCA-associated vasculitis at diagnosis. Clin Exp Nephrol. 2019;23(2):223–230. doi:10.1007/s10157-018-1634-7
   Web of Science ®Google Scholar
• Deshayes S, Aouba A, Khoy K, Mariotte D, Lobbedez T, Silva N. Hypocomplementemia is associated with worse renal survival in ANCA-positive granulomatosis with polyangiitis and microscopic polyangiitis. PLoS One. 2018;13(4):e0195680. doi:10.1371/journal.pone.0195680
   PubMed Web of Science ®Google Scholar